Navigation Links
Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts

LAWRENCE, Mass., Oct. 1 /PRNewswire-FirstCall/ --NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has been recognized as the No. 3 Fastest Growing Company in Massachusetts by the Boston Business Journal. This is the third consecutive year that NxStage has been recognized by the Boston Business Journal as one of the fastest growing companies for its list, which this year ranks the "Fastest Growing Public Companies" by revenue growth from 2006 to 2008.

"We are pleased to be recognized by the Boston Business Journal for the rapid growth we have achieved as an innovative, market pioneer," said Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage Medical, Inc. "Our growth can be attributed, in part, to our continued efforts in developing the home hemodialysis market with the industry's only portable, easy-to-use home hemodialysis machine - the NxStage System One(TM), and our market share gains within the critical care market. We also further strengthened our revenue base through the strategic acquisition of Medisystems®, our in-center business, in late 2007."

The NxStage System One is the first truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration. Its simplicity and compact size are intended to allow ease-of-use and to give patients the opportunity to travel with their therapy with their doctor's approval. It plugs into standard electrical outlets and, unlike conventional hemodialysis systems, requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

In 2009, NxStage broadened access to its dialysis products beyond the United States for the first time through a distribution agreement that brought the NxStage System One to the U.K. and Ireland. The Company also formed a strategic business alliance with Asahi Kasei Kuraray Medical, a leading medical supply company in Japan.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end stage renal disease and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's System One and other products, changes in market adoption of home daily hemodialysis, market adoption for the System One and other products internationally, and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Kristen K. Sheppard, Esq.
    VP, Investor Relations

SOURCE NxStage Medical, Inc.

SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
2. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
3. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress
5. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
6. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
7. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
8. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
9. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
10. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
11. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
Breaking Medicine Technology:
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
Breaking Medicine News(10 mins):